Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 9/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893700 | 0.84 | RXFP1 (0.78) | RXFP1THRBTP53MAPTGAA | |
| SCHEMBL1882663 | 0.82 | RXFP1 (0.64) | RXFP1THRBTP53MAPTGAA | |
| SCHEMBL1890523 | 0.82 | RXFP1 (0.60) | RXFP1THRBTP53MAPTGAA | |
| SCHEMBL1887765 | 0.80 | RXFP1 (0.63) | RXFP1THRBTP53MAPTGAA | |
| SCHEMBL1887148 | 0.76 | MAPK1 (0.49) | RXFP1THRBTP53MAPTGAA | |
| SCHEMBL1888933 | 0.75 | MAPT (0.60) | RXFP1THRBTP53MAPTGAA | |
| SCHEMBL1887674 | 0.75 | TP53 (0.64) | RXFP1THRBTP53MAPTGAA | |
| SCHEMBL1890325 | 0.74 | TP53 (0.55) | RXFP1THRBTP53MAPTGAA | |
| SCHEMBL1885586 | 0.73 | TP53 (0.55) | RXFP1THRBTP53MAPTGAA | |
| SCHEMBL1887201 | 0.73 | TP53 (0.56) | RXFP1THRBTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | claimed |
| WO-2006014647-A2 | CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF | ATHERSYS, INC. (US) | 2006-02-09 | — | — | WO | claimed |
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| WO-2006014647-A2 | CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF | ATHERSYS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | FEN1, UNG, POLH | RXFP1 4698/4885THRB 3571/4885TP53 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.